Publications

2018

Schreiber, G., et al. "Frequent source plasma donors are not at risk of iron depletion: the Ferritin Levels in Plasma Donor (FLIPD) study" Transfusion, 2018, doi:10.1111/trf.14489

Cervenakova, L., et al. “Creutzfeldt-Jakob disease and blood transfusion safety.” Vox Sanguinis, 2018, doi:10.1111/vox.12631.

2017

Cervenakova, Larisa. Creutzfeldt-Jakob disease and blood transfusion: safe or not safe? Transfusion, 2017 Aug;57(8):1851-1853.

2016

Odnoletkova, I. “Cost-Effectiveness of Prophylaxis Compared to On-Demand Treatment in Severe Haemophilia a. Systematic Review.” Value in Health, vol. 19, no. 7, 2016, doi:10.1016/j.jval.2016.09.1457.

Odnoletkova, I. “Review of National Health Technology Assessment Reports on Treatment of Severe Haemophilia A.” Value in Health, vol. 19, no. 7, 2016, doi:10.1016/j.jval.2016.09.1472.

Skinner, M. et al. Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products. Transfusion. 2016 Sep 7. doi: 10.1111/trf.13764.

Farcet, M. et al. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. Transfusion. 2016 Feb 24;56(2):383-91.

2015

Bult, JM, Farrugia A, Penrod J. The Ethics of Paid Plasma Donation: A Plea for Patient Centeredness. HEC Forum. 2015 Dec; 27(4): 417-29. doi: 10.1007/s10730-014-9253-5. PMID: 25234254.

Farrugia A & Penrod J (2015, Dec.) Errors and Omissions: Donor Compensation Policies and Richard Titmuss. HEC Forum. 2015 Dec; 27(4):319-30. doi: 10.1007/s10730-015-9267-7. PMID: 25680344.

Schreiber G, Sc.D. & Klein H, M.D. (2015, July). Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. Transfusion, Vol. 55, Issue S2, (pages S36–S46).

Farrugia A et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion. 2015 May;55(5):1067-74. doi: 10.1111/trf.12939. Epub 2014 Dec 22. PMID: 25532440.

2014

Farrugia A & Quinti I. Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacy. Front Immunol. 2014 Dec 23;5:665. doi: 10.3389/fimmu.2014.00665. eCollection 2014. PMID: 25566269 [PubMed] PMCID: PMC4274962.

Farrugia A, Iorio A., Key N, Peyvandi F (2014, May 1). Joint WFH-ISTH session: issues in clinical trial design. National Center for Biotechnology Information. 2014 May; 20 Suppl 4:137-44. doi: 10.1111/hae.12415.

Farrugia A et al. Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin. J Clin Immunol. 2014 Feb;34(2):233-44. doi: 10.1007/s10875-013-9975-1. Epub 2013 Dec 12. PMID: 24338563.

Farrugia A, Vamvakas E. "Toward a Patient-based Paradigm for Blood Transfusion." J Blood Med. (2014 Jan). 31;5:5-13. doi: 10.2147/JBM.S55769. eCollection.

2013

Farrugia A, Gathmann B, Stonebraker JS. "Modeling Primary Immunodeficiency Disease Epidemiology and its Treatment to Estimate Latent Therapeutic Demand for Immunoglobulin." J Clin Immunol. 34(2):233-44. doi: 10.1007/s10875-013-9975-1. Epub 2013 Dec 12. PMID: 24338563.

Bansal M, et al. "Choice of Fluids in Severe Septic Patients - a Cost-Effectiveness Analysis." PMID: 24330133. Reviews on Recent Clinical Trials. 2014;9(1):21-30.

Balboni S, et al. "Relative Survival Benefit and Morbidity with Fluids in Severe Sepsis-A Network Meta-Analysis of Alternative Therapies." Current Drug Safety. (2013, Sept.) 8(4):236-45. PMID: 23909705.

Farrugia A., et al. "Treatment for Life for Severe Haemophilia A - A Cost-Utility model for Prophylaxis vs. On-Demand Treatment." Haemophilia. PMID: 23534877. (2013, July). 19(4):e228-38. doi: 10.1111/hae.12121. Epub.

Stonebraker J, Farrugia A, Gathman B. “A Decision Analysis Model to Estimate Latent Therapeutic Demand for Immunoglobulin Therapy in Primary Immunodeficiencies.” 15th Meeting of the European Society Immunodeficiencies (2012, Florence, Italy), 29–34. Proceedings. Bologna, Italy: Monduzzi Editore International Proceedings Division [MEDIMOND].

2012

Farrugia A, Cassar J. "Is self-sufficiency in haemotherapies a practical or necessary goal?" Blood Transfus. (2013, April). 11(2):183-92. doi: 10.2450/2012.0148-12. Epub 2012 Dec 13. PMID: 23245724. Review.Fereydoun A, et al. "External Financial Aid to Blood Transfusion Services in sub-Saharan Africa: a Need for Reflection." PLoS medicine 9.9 (2012): e1001309.

Farrugia A, et al. "Colloid Treatment in Sepsis Patients in Intensive Care – Use of Albumin Vs Hydroxyethyl Starch (HES) Is Cost-Effective in a Decision Analysis." Vox Sanguinis 103.Suppl. 1 (2012): 238. Print.

Farrugia A, O'Mahony B, Cassar J. "Health Technology Assessment and Haemophilia." Haemophilia: the official journal of the World Federation of Hemophilia 18.2 (2012): 152–157.

Farrugia A, Penrod J, Bult JM. "Letter to the editor--Response to 'How Expanding Voluntary Non-remunerated Blood Donations Would Benefit Patients, Donors and Healthcare systems?'--F. Rossi, R. Perry, J. De Wit,T. Evers & G. Folléa, Vox Sanguinis DOI: 10.1111/j.1423-0410.2011.01495.x." Vox sanguinis 102.3 (2012): 269–270.

Farrugia A, Stonebraker J, Gathmann B. "A Decision Analysis Model For Estimating Latent Therapeutic Demand For Immunoglobulin Therapy In Primary Immune Deficiencies." J Clin Immunol 32.Suppl 1 (2012): S1–S379. Print.

Farrugia A "The Boldt Affair: Correcting a Collective Failure." Anesthesia and analgesia 115.1 (2012): 207.

Farrugia A & Cassar J "Plasma-derived Medicines: Access and Usage Issues." Blood transfusion = Trasfusione del sangue 10.3 (2012): 273–278.

Farrugia A & Gustafson M "Assessing Causality in the Transmission of Viruses by Blood Products." Transfusion 52.7 (2012): 1598; author reply 1598–1599.

Gustafson M & Farrugia A "Albumin from Rice: Why and Wherefore?" Proceedings of the National Academy of Sciences of the United States of America 109.14 (2012): E775.

Stonebraker J & Farrugia A "Using Decision Analysis to Model Latent Therapeutic Demand for Immunoglobulin in Treating CVID." J Clin Immunolo 32.399 (2012): n. pag. Print.

2011

Kimber MC, Gustafson M, Farrugia A. Response to Laub et al., 'Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations', Vox Sanguinis (2010) 99, 220-231. Vox Sang. 2011 May;100(4):438; author reply 439. doi: 10.1111/j.1423-0410.2010.01448.x. PMID: 21488883

Media and Information

PPTA News

2018 Plasma Protein Forum Highlights +

Opening Session: Jan M. Bult, President and CEO of PPTA, opened the 2018 Plasma Protein Forum by welcoming attendees to Washington, DC. He then introduced the “How Is Your Day?” campaign to PPTA’s North America audience, highlighting the campaign’s goals and purpose. Mr. Bult acknowledged attendees living with rare diseases who have offered testimonials in support of the campaign – Tim Frost, Ed Burke, Chris Templin, and Terry Halper.
Read More
PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans” +

The article, “How Blood-Plasma Companies Target the Poorest Americans,” by H. Luke Shaefer and Analidis Ochoa, published in The Atlantic on March 15, was unfair to plasma donors as well as to individuals living with rare, genetic, and chronic diseases who rely on access to plasma protein therapies. Plasma donors are due our gratitude and respect, not sweeping negative characterizations.
Read More
Highlights from the 2018 IPPC +

Mr. Jan M. Bult, President & CEO, PPTA, opened the well-attended IPPC 2018 by welcoming the more than 300 attendees to Budapest. PPTA thanks its sponsors who help make the IPPC possible every year.
Read More

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.

Subscribe to The Source

Read the current issue

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.